&NA;TA0201 (T 0201), an orally active, selective endothelin-Areceptor antagonist, is a derivative of TA0115 and is under development by Tanabe Seiyaku in Japan. It may have potential in the treatment of heart failure and is in phase I clinical investigation. It is also in preclinical investigation in pulmonary hypertension and reperfusion injury.